Apogee Therapeutics (APGE) reported a Q1 net loss Monday of $55.3 million, widening from a loss of $32.1 million a year earlier.
Analysts polled by FactSet expected a loss of $72.3 million.
The company reported no revenue for the quarter ended March 31, as expected by analysts.
Apogee reported cash, cash equivalents and marketable securities of $681.4 million as of March 31. These should be enough to allow the company to fund its operating expenses into Q1 2028, it said.
Apogee shares were up 5.6% in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.